What happened with TSHA today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Taysha Gene Therapies is a clinical-stage biotechnology company focused on diseases caused by mutations in a single gene that affect the central nervous system. Its main program, TSHA-102 for Rett syndrome, is its only therapy in clinical development. It is designed as a one-time treatment that delivers a functional form of MECP2 to central nervous system cells, with a built-in mechanism intended to limit excessive expression.
Taysha has no approved products and has never earned revenue from product sales. All revenue has come from agreements with Astellas covering Rett research and development and options to obtain licensing rights. The Rett licensing option has expired. Equity financing, rather than revenue, has been the main source of operating funds, supplemented by loans and the Astellas transactions.
The business centers on completing TSHA-102’s development and obtaining regulatory approval before it can be sold. Taysha relies exclusively on UT Southwestern for preclinical research and development, and on outside manufacturers, primarily Catalent, for production. It also expects to need additional capital to carry its programs forward.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Taysha’s prospects hinge chiefly on TSHA-102’s Rett syndrome trial results and approval, while all its reported 2025 revenue came from Astellas agreements, including revenue recognized when the Rett option expired.
Neurogene’s NGN-401 competes with Taysha’s TSHA-102 for the same Rett syndrome patients, with both gene therapies in pivotal trials and Neurogene not yet earning product-sales revenue. Watch NGN-401’s trial results for the safety and efficacy TSHA-102 will need to distinguish itself against.
Acadia Pharmaceuticals already sells DAYBUE for the Rett syndrome patients Taysha hopes to treat with TSHA-102, though their different mechanisms mean the treatments may complement each other. Watch DAYBUE sales rather than Acadia’s combined product sales, which also include its Parkinson’s disease psychosis drug NUPLAZID.
Taysha relies on Abeona Therapeutics for licensed Rett gene-therapy rights used in TSHA-102, paying milestones as development advances and potential royalties on future sales. The first patient dosed in TSHA-102’s pivotal trial in December 2025 triggered a $3 million payment to Abeona, linking its licensing revenue to Taysha’s progress.
Fed Interest Rate Decision
Taysha’s Fed-rate exposure is through its $50 million term loan: the decision can affect the prime rate that sets the interest it pays and the cash left for gene-therapy development.
Expected4.0%Last release4.0%
If it comes in above expectations
If the Fed sets rates higher than expected, broader rates may rise and lift prime; if prime exceeds the loan’s 11.5% floor, Taysha may pay more interest, leaving less cash for developing TSHA-102 and its other programs.
If it comes in below expectations
If the Fed sets rates lower than expected, broader rates may fall and bring prime down; when the prime-rate formula applies, Taysha may pay less interest, leaving more cash for developing TSHA-102 and its other programs.
Taysha Gene Therapies, Inc. earningsThis company
Taysha Gene Therapies’ cash use and TSHA-102 trial progress will show how far its funding can carry the Rett program.
Read operating cash outflow alongside TSHA-102’s trial progress. Lower outflow with the trial advancing would mean existing funds go further; rising outflow with delays would shorten the cash runway—the time available to fund operations—and increase pressure to raise capital, slow development or find a partner.
Acadia Pharmaceuticals Inc. earningsACAD
Acadia Pharmaceuticals’ DAYBUE sales will show demand for an existing Rett treatment, giving Taysha a read on the patient market TSHA-102 would enter.
Focus on DAYBUE sales, not Acadia’s total product sales, which also include NUPLAZID, its drug for Parkinson’s disease psychosis. Stronger DAYBUE sales would show more Rett patients receiving drug treatment and suggest a broader treated market for TSHA-102 to enter, but would not establish demand for gene therapy. Weaker sales would point to a smaller or harder-to-reach market for current treatment, not prove TSHA-102 has no opportunity.
